Confirms Receipt of Two Director Nominees from Daniel J. ManglessStockholders Are Not Required to Take Action at This TimeCELEBRATION, Fla., ...

Zevra Therapeutics’ Miplyffa approved for Niemann-Pick type C. Read why ZVRA stock presents both potential and risks for long-term investors.

Whilst it may not be a huge deal, we thought it was good to see that the Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Independent Director, John Bode, recently bought US$80k worth of stock, for US$7.96 ...

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) will likely be announcing its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ...

Meeting to be held in London and Zurich on March 31-April 2 hosted by Cantor Fitzgerald.Light Up your Portfolio with Spark:Easily identify ...

Whilst it may not be a huge deal, we thought it was good to see that the Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Independent Director, John Bode, recently bought US$80k worth of stock, for US$7.96 per ...

Neil Mcfarlane; President, Chief Executive Officer, Director; Zevra Therapeutics Inc Joshua Schafer; Chief Commercial Officer and Executive Vice President, Business Development; Zevra Therapeutics ...

During the last three months, 5 analysts shared their evaluations of Zevra Therapeutics (NASDAQ:ZVRA), revealing diverse outlooks from bullish to bearish. The table below summarizes their recent ...

CELEBRATION, Fla. (AP) — CELEBRATION, Fla. (AP) — Zevra Therapeutics, Inc. (ZVRA) on Tuesday reported a loss of $35.7 million in its fourth quarter. The Celebration, Florida-based company said it had ...

CELEBRATION, Fla. (AP) — CELEBRATION, Fla. (AP) — Zevra Therapeutics, Inc. (ZVRA) on Tuesday reported a loss of $35.7 million in its fourth quarter. The Celebration, Florida-based company said ...